About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect
's current perspective of existing information as of the date of this release. It is important to note that
's goals and expectations are not predictions of actual performance. Actual results may differ materially from
's current expectations depending upon a number of factors, risks and uncertainties affecting
's business. These factors include, among others, the inherent uncertainty associated with financial projections; successful close and subsequent integration of the Actavis acquisition and the ability to recognize the anticipated synergies and benefits of the Actavis acquisition; the anticipated size of the markets and continued demand for
's and Actavis' products; the impact of competitive products and pricing; the receipt of required regulatory approvals for the Actavis acquisition transaction (including the approval of antitrust authorities necessary to complete the acquisition); access to available financing (including financing for the acquisition) on a timely basis and on reasonable terms; risks of fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry; and such other risks and uncertainties detailed in
's periodic public filings with the Securities and Exchange Commission, including but not limited to
's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2012
's Annual Report on Form 10-K for the year ended
December 31, 2011
. Except as expressly required by law,
disclaims any intent or obligation to update these forward-looking statements.
SOURCE Watson Pharmaceuticals, Inc.